Educate Why Aduhelm Isn't a Miracle for Alzheimer's

You'll hear controversy about Aduhelm (aducanumab), the first new med for Alzheimer's disease in almost 20 years.

It's a monoclonal antibody given as an IV infusion every 4 weeks.

Patients with Alzheimer's and their families are often looking for a glimmer of hope. But Aduhelm doesn't seem to be it.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote